About our business

1nhaler Ltd is a pioneering inhalable drug delivery device developer based in Scotland.

We are developing a pop-up cardboard inhaler: a single-dose dry-powder inhaler that is simple to use,  cheap to make and small enough to slip into a wallet. Always there, where and when you need it.

Propellant-free and made predominantly from cardboard,  the 1nhaler transforms from a flat credit card shape into a three-dimensional inhaler.  The patent-protected membrane dispersion technology is designed to support a variety of medicines in dry-powder format.

Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s. To date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment.

New opportunities are emerging for a wide range of inhalable treatments including vaccines and medicine delivery in pandemic scenarios as well as clinical trials and supporting drug sampling.

We are interested in exploring business collaborations and welcome enquiries for our lead product and other opportunities for the novel 1nhaler platform technology.

Board of Directors

  • Jane Gaddum

    Chair

    Formerly VP Emerging Respiratory and Inflammation, Global Marketing, AZ

  • Joanne Kelley

    Non-executive Director

    Formerly, VP Business Development, AZ

  • Gordon Muirhead

    Non-executive Director

    Formerly VP Global Manufacturing & Supply, GSK

  • Lisa McMyn

    CEO and Co-founder

    Experienced business executive, product development expert and serial entrepreneur

  • Don Smith

    Inventor and Co-founder

    Award-winning creative director, innovation expert, and inventor of the 1nhaler device

Funding partners

2025 year ahead

“I am so proud of the progress our research and development team has made - led by Helen Muirhead, who was previously responsible for the development of GSK’s blockbuster inhalers. Already, we are showing data comparable with the market-leading inhaler. Our goal for 2025 is to produce clinical samples for the first human trial early 2026.”

Lisa McMyn, CEO and Co-founder